Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients.
Yuko NagaokiMichio ImamuraYuji TeraokaKei MorioHatsue FujinoAtsushi OnoTakashi NakaharaEisuke MurakamiMasami YamauchiTomokazu KawaokaDaiki MikiMasataka TsugeAkira HiramatsuC Nelson HayesKazuaki ChayamaHiroshi AikataPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
Achievement of SVR by DAA therapy reduces the risk of HCC development and prolongs survival, similar to theresults achieved with IFN-based therapy, but portal hypertension is not immediately improved in compensated liver cirrhosis patients.